Showing results (641-650 of 675) with videos related to
Sort By:
Pageof 68
Nature|April 14, 2006
Production of the antimalarial drug precursor artemisinic acid in engineered yeastDae-Kyun Ro, Eric M Paradise, Mario Ouellet, et al.Bone Marrow Transplantation|November 1, 2016
An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognosticationV V Maka, L-P Koh, C Diong, et al.Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association|March 21, 2014
Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancerK D Crew, K A Ho, P Brown, et al.Biomaterials Advances|May 7, 2022
Doxorubicin nanoformulations on therapy against cancer: An overview from the last 10 yearsNatália A D'Angelo, Mariana A Noronha, Mayra C C Câmara, et al.Nature|September 6, 2000
Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)KgammaT Sasaki, J Irie-Sasaki, Y Horie, et al.Current Oncology (Toronto, Ont.)|January 5, 2017
Socioeconomic status and lifestyle behaviours in cancer survivors: smoking and physical activityH Naik, X Qiu, M C Brown, et al.Nature|May 9, 2001
ICOS is essential for effective T-helper-cell responsesA Tafuri, A Shahinian, F Bladt, et al.Blood|July 27, 2018
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AMLAmir T Fathi, Harry P Erba, Jeffrey E Lancet, et al.JAMA|May 26, 2018
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical TrialGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.Blood|December 3, 2017
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemiaEytan M Stein, Roland B Walter, Harry P Erba, et al.Pageof 68